Evidence map›Paper›PMID 33376181›Full record

ArticleBMJ open2020

Medical Marijuana and Opioids (MEMO) Study: protocol of a longitudinal cohort study to examine if medical cannabis reduces opioid use among adults with chronic pain.

Chinazo O Cunningham, Joanna L Starrels, Chenshu Zhang, Marcus A Bachhuber, Nancy L Sohler, Frances R Levin, Haruka Minami, Deepika E Slawek, Julia H Arnsten

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03268551 completednot on this map

Does Medical Cannabis Reduce Opioid Analgesics in HIV+ and HIV- Adults With Pain?

TypeobservationalSponsorAlbert Einstein College of MedicineRan2018 to 2023Enrolled257ConditionsOpioid Use, Marijuana, Chronic Pain, HIV/AIDS
NCT07148206 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

TypeinterventionalSponsorMontefiore Medical CenterRan2026 to 2028Enrolled40ConditionsOpioid Use DisorderArmsDronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Chinazo O CunninghamDivision of General Internal Medicine, Montefiore Health System, Bronx, New York, USA chinazo.cunningham@einsteinmed.org.ORCID 0000-0002-7930-313X
Joanna L StarrelsDivision of General Internal Medicine, Montefiore Health System, Bronx, New York, USA.
Chenshu ZhangDivision of General Internal Medicine, Montefiore Health System, Bronx, New York, USA.
Marcus A BachhuberSection of Community and Population Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Nancy L SohlerSchool of Medicine, City University of New York, New York, New York, USA.
Frances R LevinDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA.
Haruka MinamiPsychology Department, Fordham University, Bronx, New York, USA.
Deepika E SlawekDivision of General Internal Medicine, Montefiore Health System, Bronx, New York, USA.
Julia H ArnstenDivision of General Internal Medicine, Montefiore Health System, Bronx, New York, USA.
Montefiore Health System · USCity University of New York · USColumbia University Irving Medical Center · USFordham University · USLouisiana State University Health Sciences Center New Orleans · US

Funding

Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vilma Gabbay · 2017 to 2026
$28.3M
Does medical cannabis reduce opioid analgesics in HIV+ and HIV- adults with pain?R01DA044171 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI ARNSTEN, JULIA H. · 2017 to 2021
$3.8M
Mentoring researchers on drug abuse and HIVK24DA036955 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CUNNINGHAM, CHINAZO · 2014 to 2019
$911k
Mentoring Junior Investigators to Tackle the Opioid EpidemicK24DA046309 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI STARRELS, JOANNA L. · 2018 to 2023
$876k
NIAID NIH HHS P30 AI124414NIDA NIH HHS K24 DA036955NIDA NIH HHS K24 DA046309NIDA NIH HHS R01 DA044171
6 · The paper itself

Abstract

introductionIn the USA, opioid analgesic use and overdoses have increased dramatically. One rapidly expanding strategy to manage chronic pain in the context of this epidemic is medical cannabis. Cannabis has analgesic effects, but it also has potential adverse effects. Further, its impact on opioid analgesic use is not well studied. Managing pain in people living with HIV is particularly challenging, given the high prevalence of opioid analgesic and cannabis use. This study's overarching goal is to understand how medical cannabis use affects opioid analgesic use, with attention to Δ9-tetrahydrocannabinol and cannabidiol content, HIV outcomes and adverse events. METHODS AND ANALYSES: We are conducting a cohort study of 250 adults with and without HIV infection with (a) severe or chronic pain, (b) current opioid use and (c) who are newly certified for medical cannabis in New York. Over 18 months, we collect data via in-person visits every 3 months and web-based questionnaires every 2 weeks. Data sources include: questionnaires; medical, pharmacy and Prescription Monitoring Program records; urine and blood samples; and physical function tests. Using marginal structural models and comparisons within participants' 2-week time periods (unit of analysis), we will examine how medical cannabis use (primary exposure) affects (1) opioid analgesic use (primary outcome), (2) HIV outcomes (HIV viral load, CD4 count, antiretroviral adherence, HIV risk behaviours) and (3) adverse events (cannabis use disorder, illicit drug use, diversion, overdose/deaths, accidents/injuries, acute care utilisation). ETHICS AND DISSEMINATION: This study is approved by the Montefiore Medical Center/Albert Einstein College of Medicine institutional review board. Findings will be disseminated through conferences, peer-reviewed publications and meetings with medical cannabis stakeholders. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registry (NCT03268551); Pre-results.

Indexed as

Chronic PainHIV InfectionsMedical MarijuanaAdultAnalgesics, OpioidCohort StudiesHumansLongitudinal StudiesNew YorkAnalgesics, OpioidMedical Marijuanacomplementary medicineHIV & AIDSpain managementstatistics & research methods

Identifiers

PMID33376181
PMCPMC7778768
OpenAlexW3116039148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.